source
- Bristol Myers appoints Cristian Massacesi as head of R&D as Robert Plenge exitsBristol Myers Squibb announced a reorganization of its research and development organization, merging the research and development units under a single leader. Cristian Massacesi, currently chief…
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.BioPharma Dive · 10h ago↗ source
- PepGen soars on promising early data for muscular dystrophy drugWhile from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.